A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 338-344

  Lee, Sooyong ^a   Yoon, Seunghee ^a   Kim, Dong Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

Apoptosis; Cisplatin; Cisplatin resistance; ERK1 2; MAPK; Nuclear localization; OVCAR 3 cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHORBOL 13 ACETATE 12 MYRISTATE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SERUM; STAINING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTADIENES; CASPASE 3; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NITRILES; OVARIAN NEOPLASMS; PHOSPHORYLATION; TETRADECANOYLPHORBOL ACETATE;

EID: 33846394128     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.040     Document Type: Article

References (31)

1. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J. 9 (1995) 726-735
2. Pearson G., Robinson F., Gibson T.B., Xu B.E., Karandikar M., Berman K., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001) 153-183
3. Chang L., and Karin M. Mammalian MAP kinase signaling cascades. Nature 410 (2001) 37-40
4. Jaaro H., Rubinfeld H., Hanoch T., and Seger R. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3742-3747
5. mapkk) in fibroblasts. J. Cell Biol. 122 (1993) 1079-1088
6. Adachi M., Fukuda M., and Nishida E. Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimmer. EMBO J. 18 (1999) 5347-5358
7. Robinson M.J., Goldsmith E., White M.A., and Cobb M.H. Constitutive active ERK2 MAP kinase is sufficient for neurite outgrowth and cell transformation when targeted to the nucleus. Curr. Biol. 8 (1998) 1141-1150
8. Vicent S., Lopez-Picazo J.M., Toledo G., Lozano M.D., Torre W., Garcia-Corchon C., et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br. J. Cancer 90 (2004) 1047-1052
9. Persons D.L., Yazlovitskaya E.M., Cui W., and Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5 (1999) 1007-1014
10. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitized human ovarian cancer cell line. J. Biol. Chem. 274 (1999) 31648-31654
11. Cui W., Yazlovitskaya E.M., Mayo M.S., Pelling J.C., and Persons D.L. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinase 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol. Carcinog. 29 (2000) 219-228
12. Mandic A., Viktorsson K., Heiden T., Hansson J., and Shoshan M.C. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 11 (2001) 11-19
13. Wang X., Martindale X., and Holbrook J.L. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 (2000) 39435-39443
14. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Ea C.K., and Cheng A.L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation. Biochem. Pharmacol. 63 (2002) 1423-1430
15. Lee E.K., Regenold W.T., and Shapiro R. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-Cancer Drugs 13 (2002) 859-868
16. Woessmann W., Chen X., and Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 50 (2002) 397-404
17. Rice P.L., Beard K.S., Driggers L.J., and Ahnen D.J. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res. 64 (2004) 8148-8151
18. Wu J., Wong W.W., Khosravi F., Minden M.D., and Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastin-induced apoptosis. Cancer Res. 64 (2004) 6461-6468
19. Ajenjo N., Canon E., Sanchez-Perez I., Matallanas D., Leon J., Perona R., and Crespo P. Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. J. Biol. Chem. 279 (2004) 32813-32823
20. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 97 (2005) 26-34
21. Wolf I., Rubinfeld H., Yoon S., Marmor G., Hanoch T., and Seger R. Involvement of the activation loop of ERK in the detachment from cytosolic anchoring. J. Biol. Chem. 276 (2001) 24490-24497
22. Arany I., Megyesi J.K., Kaneto H., Price P.M., and Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol., Renal Fluid Electrolyte Physiol. 287 (2004) F543-F549
23. Persons D.L., Yazlovitskaya E.M., and Pelling J.C. Effect of extracellular signal regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 275 (2000) 35778-35785
24. 2. Role in cell survival following oxidant injury. J. Biol. Chem. 271 (1996) 4138-4142
25. Meng X.W., Heldebrant M.P., and Kaufmann S.H. Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain. J. Biol. Chem. 277 (2002) 3776-3783
26. Lai J.M., Wu S., Huang D.Y., and Chang Z.F. Cytosolic retention of phosphorylated extracellular signal-regulated kinase and a Rho-associated kinase-mediated signal impair expression of p21Cip1/Waf1 in phorbol 12-myristate13-acetate-induced apoptotic cells. Mol. Cell. Biol. 22 (2002) 7581-7592
27. Takagi Y., Du J., Ma X.Y., Nakamura I., and Nagase F. Phorbol 12-myristate 13-acetate protects Jurkat cells from Methylglyoxal-induced apoptosis by preventing c-Jun N-terminal kinase-mediated leakage of cytochrome c in an extracellular signal-regulated kinase-dependent manner. Mol. Pharmacol. 65 (2004) 778-787
28. Besson A., Davy A., Robbins S.M., and Yong V.W. Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 20 (2001) 7398-7407
29. Clark J.A., Black A.R., Leontieva O.V., Frey M.R., Pysz M.A., Kunneva L., et al. Involvement of the ERK signaling cascade in protein kinase c-mediated cell cycle arrest in intestinal epithelial cells. J. Biol. Chem. 279 (2004) 9233-9247
30. Grammer T.C., and Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 14 (1997) 1635-1642
31. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., et al. Constitutive activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822